Abstract
Some papers reported the development of adverse drug reactions in patients with Down’s syndrome during the treatment with antiepileptic drugs. However, at this time, no data have been published concerning the development of tremor in patients with Down’s syndrome treated with sodium valproate.
We report a 17-year-old man with epilepsy and Down’s syndrome who experienced tremor during the treatment with a low dosage of sodium valproate. The Naranjo probability scale documented a possible association between tremor and sodium valproate. Sodium valproate was changed to lamotrigine with both a rapid improvement of tremor and an optimal control of symptoms.
In conclusion we documented that sodium valproate is able to induce in a patient with epilepsy and Down‘s syndrome, the development of tremor probably through the decreased activity of GABAergic neurotrasmission; however, further studies may be performed in order to validate this observation.
Keywords: Down syndrome patients, epilepsy, anticonvulsant, sodium valproate, tremor.
Current Drug Safety
Title:Sodium Valproate Induced Tremor in a Patient with Epilepsy and Down's Syndrome
Volume: 8 Issue: 1
Author(s): Antonio Siniscalchi, Luca Gallelli, Simona Loizzo, Avenoso Tiziana, Emilio Russo and Giovambattista De Sarro
Affiliation:
Keywords: Down syndrome patients, epilepsy, anticonvulsant, sodium valproate, tremor.
Abstract: Some papers reported the development of adverse drug reactions in patients with Down’s syndrome during the treatment with antiepileptic drugs. However, at this time, no data have been published concerning the development of tremor in patients with Down’s syndrome treated with sodium valproate.
We report a 17-year-old man with epilepsy and Down’s syndrome who experienced tremor during the treatment with a low dosage of sodium valproate. The Naranjo probability scale documented a possible association between tremor and sodium valproate. Sodium valproate was changed to lamotrigine with both a rapid improvement of tremor and an optimal control of symptoms.
In conclusion we documented that sodium valproate is able to induce in a patient with epilepsy and Down‘s syndrome, the development of tremor probably through the decreased activity of GABAergic neurotrasmission; however, further studies may be performed in order to validate this observation.
Export Options
About this article
Cite this article as:
Siniscalchi Antonio, Gallelli Luca, Loizzo Simona, Tiziana Avenoso, Russo Emilio and Sarro Giovambattista De, Sodium Valproate Induced Tremor in a Patient with Epilepsy and Down's Syndrome, Current Drug Safety 2013; 8 (1) . https://dx.doi.org/10.2174/1574886311308010010
DOI https://dx.doi.org/10.2174/1574886311308010010 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
IBD Modern Concepts, Nano Drug Delivery and Patents: An Update
Recent Patents on Nanomedicine Role of Methylene Blue in Trauma Neuroprotection and Neuropsychiatric Diseases
CNS & Neurological Disorders - Drug Targets Src Family Kinases in the Central Nervous System: Their Emerging Role in Pathophysiology of Migraine and Neuropathic Pain
Current Neuropharmacology Sugars that Glow in the Dark: Fluorescent Tagged Glucose Bioprobes and their Facilitation of the Drug Discovery Process
Current Medicinal Chemistry Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?
Current Alzheimer Research Analysis of NCL Proteins from an Evolutionary Standpoint
Current Genomics Complex and Differential Glial Responses in Alzheimer´s Disease and Ageing
Current Alzheimer Research Primary and Secondary Insomnia: Prevalence, Causes and Current Therapeutics
Current Medicinal Chemistry - Central Nervous System Agents The Role of mGlu Receptors in Hippocampal Plasticity Deficits in Neurological and Psychiatric Disorders: Implications for Allosteric Modulators as Novel Therapeutic Strategies
Current Neuropharmacology Obesity Pharmacotherapy: Current Perspectives and Future Directions
Current Cardiology Reviews GABAB Receptors-Associated Proteins: Potential Drug Targets in Neurological Disorders?
Current Drug Targets Nanotechnological Advances in the Treatment of Epilepsy
CNS & Neurological Disorders - Drug Targets Specific Roles of NMDA Receptor Subunits in Mental Disorders
Current Molecular Medicine Editorial [Hot Topic: Ion Channels as Therapeutic Targets for Neuropathic Pain (Executive Editor: Char-Chang Shieh)]
Current Pharmaceutical Design Structural Properties of the NMDA Receptor and the Design of Neuroprotective Therapies
Mini-Reviews in Medicinal Chemistry Synthesis, Molecular Modeling and Biological Evaluation of 5-arylidene-N,N-diethylthiobarbiturates as Potential α-glucosidase Inhibitors
Medicinal Chemistry High Throughput Screening Assay of α1G T-type Ca2+ Channels and Comparison with Patch-Clamp Studies
Combinatorial Chemistry & High Throughput Screening Advances in Metal-organic Frameworks (MOFs) based Biosensors for Diagnosis: An Update
Current Topics in Medicinal Chemistry Understanding Genotypes and Phenotypes of the Mutations in Voltage- Gated Sodium Channel α Subunits in Epilepsy
CNS & Neurological Disorders - Drug Targets Adenosine Receptor Ligands-Recent Developments Part I. Agonists
Current Medicinal Chemistry